



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/025626
- (22) **International Filing Date:**
02 April 2021 (02.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/005,130 03 April 2020 (03.04.2020) US
63/079,810 17 September 2020 (17.09.2020) US
- (71) **Applicant:** ALECTOR LLC [US/US]; 131 Oyster Point Blvd, Suite 600, South San Francisco, California 94080 (US).
- (72) **Inventors:** PAUL, Robert; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). WARD, Michael F.; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). LONG, Hua; c/o Alector LLC, 131

Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US). SIDDQUI, Omer Rizwan; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). ROSENTHAL, Arnon; c/o Alector LLC, 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US). YEH, Felix Leejia; c/o Alector LLC, 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US). JACKSON, Sam; c/o Alector LLC, 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US).

(74) **Agent:** PESIN-FULOP, Jillian; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** METHODS OF USE OF ANTI-TREM2 ANTIBODIES




FIG. 3A

(57) **Abstract:** The present disclosure is generally directed to the use of compositions that include antibodies, *e.g.*, monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, *etc.*, that specifically bind one or more epitopes within a TREM2 protein, *e.g.*, human TREM2, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*